Home
IMRX
IMRX News

Latest Immuneering Corporation (IMRX) News on March 30, 2025

Immuneering Corporation Announces Grant of Inducement Award

GlobeNewswire

9 days ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire

10 days ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

GlobeNewswire

10 days ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Slides As Insider Purchases Lose Another US$186k

Simply Wall St.

25 days ago

Immuneering Slides As Insider Purchases Lose Another US$186k

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

GlobeNewswire

2 months ago

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

2 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

Simply Wall St.

2 months ago

Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

GlobeNewswire

3 months ago

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Why Is Immuneering Stock Trading Higher On Tuesday?

Benzinga

3 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

MT Newswires

3 months ago

Immuneering Says New Phase 2a Pancreatic Cancer Trial Data Show Better Response, Disease Control Rates

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

GlobeNewswire

3 months ago

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Aadi Bioscience Leads 3 Promising US Penny Stocks

Simply Wall St.

3 months ago

Aadi Bioscience Leads 3 Promising US Penny Stocks

Immuneering Launches Pancreatic Cancer Advisory Board

GlobeNewswire

3 months ago

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

GlobeNewswire

3 months ago

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Benzinga

4 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

MT Newswires

4 months ago

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

GlobeNewswire

4 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

GlobeNewswire

4 months ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

Simply Wall St.

4 months ago

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

5 months ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

Zacks

5 months ago

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

MT Newswires

6 months ago

Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

GlobeNewswire

6 months ago

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation

Simply Wall St.

6 months ago

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

Zacks

6 months ago

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

MT Newswires

7 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

Benzinga

7 months ago

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

MT Newswires

7 months ago

Top Premarket Gainers

MT Newswires

7 months ago

Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating

MT Newswires

7 months ago

Update: Immuneering Shares Surge Premarket as 'Positive' Data Seen in Phase 2a Pancreatic Cancer Trial

MT Newswires

7 months ago

Immuneering Shares Surge After 'Positive' Data in Phase 2a Pancreatic Cancer Trial

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

GlobeNewswire

7 months ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

7 months ago

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock

Simply Wall St.

7 months ago

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock

MT Newswires

8 months ago

Chardan Adjusts Immuneering Price Target to $16 From $12, Maintains Buy Rating

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

8 months ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

GlobeNewswire

8 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 06/18/2024

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 06/17/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/14/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/13/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/12/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/11/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/10/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/07/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/06/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/05/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/04/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 06/03/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/31/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/30/2024

Immuneering to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

10 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/29/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/28/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/24/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/23/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/22/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/21/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/20/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/17/2024

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 05/16/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/15/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/14/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/13/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/10/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/09/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/08/2024

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

Simply Wall St.

a year ago

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/07/2024

Immuneering Recognizes Melanoma Awareness Month

GlobeNewswire

a year ago

Immuneering Recognizes Melanoma Awareness Month

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/06/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/03/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/02/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 05/01/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/30/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/29/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/26/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/25/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/24/2024

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 04/23/2024

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

GlobeNewswire

a year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

a year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

GlobeNewswire

a year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Director Acquires 7.5% More Stock

Simply Wall St.

a year ago

Immuneering Director Acquires 7.5% More Stock

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Zacks

a year ago

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

GlobeNewswire

a year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

GlobeNewswire

a year ago

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

GlobeNewswire

a year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

GlobeNewswire

a year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

GlobeNewswire

a year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

GuruFocus.com

a year ago

Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

GlobeNewswire

a year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

InvestorPlace

a year ago

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Immuneering Announces Participation in February Investor Conferences

GlobeNewswire

a year ago

Immuneering Announces Participation in February Investor Conferences

Thomson Reuters StreetEvents

a year ago

Q2 2024 LSI Industries Inc Earnings Call

LSI Industries Inc. (LYTS) Reports Q2 Fiscal 2024 Results: Net Income Dips Slightly Amidst ...

GuruFocus.com

a year ago

LSI Industries Inc. (LYTS) Reports Q2 Fiscal 2024 Results: Net Income Dips Slightly Amidst ...

Analysts Are Updating Their Citizens & Northern Corporation (NASDAQ:CZNC) Estimates After Its Full-Year Results

Simply Wall St.

a year ago

Analysts Are Updating Their Citizens & Northern Corporation (NASDAQ:CZNC) Estimates After Its Full-Year Results

ChargePoint Becomes One of the First EV Charging Providers to Receive FedRAMP Approval for the Implementation of Federal EV Charging Infrastructure

Business Wire

a year ago

ChargePoint Becomes One of the First EV Charging Providers to Receive FedRAMP Approval for the Implementation of Federal EV Charging Infrastructure

Share on Social Networks: